, 1986.
141. Kampmann JP, Johansen K, Hansen JM, Helwig J: Propylthiouracil in human milk: Revision of a dogma. Lancet 1:736, 1980.
141a. Azizi F, Khoshniat M, Bahrainian M, Hedayati M. Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J Clin Endocrinol Metab 85:3233-3238, 2000.
142. Wiberg JJ, Nuttall FQ: Methimazole toxicity from high doses. Ann Intern Med 77:414, 1972.
143. Chevalley J, McGavack TH, Kenigsberg S, Pearson S: A four- year study of the treatment of hyperthyroidism with methimazole. J Clin Endocrinol Metab 14:948, 1954.
144. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 150:621-624, 1990.
145. Tamai H, Takaichi Y, Morita T, Komaki G, Matsubayashi S, Kuma K, Walter Jr RM, Kumagai LF, Nagataki S: Methimazole- induced agranulocytosis in Japanese patients with Graves’ disease. Clin Endocrinol 30:525-530, 1989.
146. Amrhein JA, Kenny F, Ross D: Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapy. J Pediatr 76:54, 1970.
147. Pacini F, Sridama V, Refetoff S: Multiple complications of propylthiouracil treatment: Granulocytopenia, eosinophilia, skin reaction, and hepatitis with lymphocyte sensitization. J Endocrinol Invest 5:403-407, 1982.
147.1 Darben T, Savige J, Prentice R, Paspaliaris B, Chick J. 1999 Pyoderma gangrenosum with secondary pyarthrosis following propylthiouracil. Australasian J Dermatol. 40:144-146.
148. Wall JR, Fang SL, Kuroki T, Ingbar SH, Braverman LE: In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves’ disease: A possible cause of antithyroid drug-induced agranulocytosis. J Clin Endocrinol Metab 58:868-872, 1984.
149. Biswas N, Ahn Y-H, Goldman JM, Schwartz JM: Case report: Aplastic anemia associated with antithyroid drugs. Am J Med Sci 301:190-194, 1991.
149.1 Breier DV, Rendo P, Gonzalez J, Shilton G, Stivel M, Goldztein S. Massive plasmocytosis due to methimazole-induced bone marrow toxicity. Amer J Hematol 67:259-261, 2001.
149.1 Gunton JE, Stiel J, Caterson RJ, McElduff A. Antithyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab 84:13-16, 1999
149.2 Guma M, Salinas I, Reverter JL, Roca J, Valls-Roc M, Juan M, Olive A. Frequency of antineutrophil cytoplasmic antibody in Gravesâ€™ disease patients treated with methimazole. J Clin Endocrinol Metab 88:2141-2146, 2003.
150. Tajiri J, Noguchi S, Murakami T, Murakami N: Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 150:621- 624, 1990.
151. Cooper DS: Antithyroid drugs. N Engl J Med 311:1353- 1362, 1984.
152. Weiss M, Hassin D, Bank H: Propylthiouracil-induced hepatic damage. Arch Intern Med 140:1184-1185, 1980.
152.1. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: What have we learned? J Clin Endocrinol Metab 82:1727-1733, 1997.
125.2 Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, Morimoto T, Corners J, Nakao K.Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves’ disease.J Bone Miner Metab. 2006;24(2):105-13.
153. Miyazono K, Okazaki T, Uchida S, Totsuka Y, Matsumoto T, Ogata E, Terakawa K, Kurihara N, Takeda T: Propylthiouracil-induced diffuse interstitial pneumonitis. Arch Intern Med 144:1764-1765, 1984.
153.1. Escobar-Morreale HF, Bravo P, Garcia-Robles R, Garcia-Larana J, de la Calle H, Sancho JM. Methimazole-induced severe aplastic anemia: unsuccessful treatment with recombinant human granulocyte-monocyte colony-stimulating factor. Thyroid 7:67-70, 1997.
153.2 Karlsson, FA; Axelsson, O; Melhus, H. Severe embryopathy and exposure to methimazole in early pregnancy. J Clin Endocrinol Metab 87 947-948 2002.
154. Tamai H, Mukuta T, Matsubayashi S, Fukata S, Komaki G, Kuma K, Kumagai LF, N